Cytokinetics Grants Equity to 18 New Hires
The South San Francisco drug developer issued stock options and restricted stock units to 18 employees as inducements to join the company.
Updated on Nov. 16, 2026 in Jobs — General

Cytokinetics, Incorporated granted stock options for 64,110 shares and 42,496 restricted stock units to 18 employees on November 13, 2026. The awards were made as material inducements to employment under Nasdaq Listing Rule 5635(c)(4).
Why it matters
Equity grants of this kind are a common tool for attracting new staff at publicly traded biotechnology companies that compete for talent. The disclosure gives investors a view of how the company is building out its workforce as it advances its drug pipeline.
The stock options carry a $56.13 exercise price, equal to the November 13, 2026 closing price, and a 10-year term. The restricted stock units vest over three years at 40%, 40% and 20%, while the options vest over four years, with the filing not stating the total dollar value of the grants.
The players
Cytokinetics, Incorporated
A South San Francisco biopharmaceutical company focused on developing treatments for cardiovascular disease, including cardiac myosin inhibitors for heart muscle disorders.
The details
The grants went to 18 employees who began work in October and November 2026, under the Amended and Restated 2004 Equity Incentive Plan. Vesting for both awards depends on each employee's continued service with the company.
Timeline
October 2026: 18 employees began employment at Cytokinetics.
November 13, 2026: Stock options and restricted stock units were granted to the 18 employees.
Q4 2026: Cytokinetics plans to submit a Supplemental New Drug Application for aficamten in non-obstructive hypertrophic cardiomyopathy.
Roadmap
Companies listed on Nasdaq use the Rule 5635(c)(4) inducement exemption to recruit talent without a shareholder vote, a tool biotechnology firms rely on heavily as they hire ahead of late-stage drug development. Cytokinetics' grants follow that pattern while the company prepares its aficamten filing for non-obstructive hypertrophic cardiomyopathy.
For job seekers, equity inducements like these signal that biotechnology employers in South San Francisco are competing on total compensation, not just base salary. Employees who join with these grants will see shares vest over several years, so their long-term pay depends on the company's stock performance.
The takeaway
Candidates weighing offers from publicly traded biotechnology firms should review vesting schedules and exercise prices alongside base pay, since equity grants can make up a large share of total compensation over time.
What happens next
Cytokinetics plans to submit a Supplemental New Drug Application for aficamten in non-obstructive hypertrophic cardiomyopathy in Q4 2026.
Further reading
Explore more Jobs — General coverage to see how employers across the region are using equity and hiring incentives.
Source note: This article includes information reported by The Manila times.










